Daratumumab with chemo for older adults with high-risk AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 study tests whether adding daratumumab to standard intensive chemotherapy (idarubicin and cytarabine) works safely in people age 60 or older with a higher-risk form of acute myeloid leukemia (AML). It may help improve outcomes, but the main goal is to find the best dosing and safety in this age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 60 years old
- Your AML is considered higher-risk (poor prognosis) by the study’s criteria
- You can receive intensive chemotherapy (your treating team says it’s appropriate) and your performance status is ECOG 2 or less
- Your organ function labs are within limits: liver enzymes < 3x normal, bilirubin < 1.5x normal, kidney filtering > 60 mL/min
- Heart function is strong enough (LVEF 50% or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a targeted drug called daratumumab to standard chemotherapy works better for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL). Daratumumab helps the immune system find and attack cancer cells.
This Phase 2 trial studies daratumumab (an antibody medicine) for adults whose rare lymph node/immune-related cancers have come back or did not respond to treatment. It may help shrink disease and improve symptoms, including for people living with HIV when their virus is well controlled.
This Phase 2 study tests whether adding daratumumab to standard chemotherapy, followed by a stem cell transplant, can improve outcomes in primary plasma cell leukemia. It aims to see how well this treatment works and whether it’s safe for people who are eligible for intensive therapy and transplant.
This trial tests a new form of chemotherapy (liposomal cytarabine-daunorubicin) for older adults with high-risk AML that has not been treated yet. It is designed for people whose AML is secondary to a previous cancer treatment or blood disorder.
This trial tests if adding the drug daratumumab can clear remaining cancer cells in people with T-cell acute lymphoblastic leukemia (T-ALL) who still have a small amount of leukemia after initial chemotherapy. It aims to reduce the risk of the cancer coming back.
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
Hear when a new Adult Patients With Adverse Risk Acute Myeloblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.